A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

iApotheca Healthcare Inc. Announces Closing of $470K Angel Funding Round

iApotheca Healthcare, the developers of a leading Canadian pharmacy software operations platform, has announced the closing of a $470k angel funding round. iApotheca will use the funds to accelerate their EconoRoute™ Prescription Delivery System through the addition of key team members, ongoing platform development and the expansion of the EconoRoute™ network.

“Prescription delivery is revolutionizing the way people interact with their chosen pharmacy,” said Spencer Turbitt, co-founder and CEO of iApotheca. “We would like to thank Leva Capital, York Angels, and Valhalla Angels for their investment in our company. Their investment and advice are allowing us to accelerate our plans to achieve our vision for the pharmacy delivery space.”

iApotheca specializes in streamlining pharmacy operations, particularly in prescription delivery service, to help pharmacies grow their revenue. In recent years, the demand for prescription delivery has seen a sharp rise. iApotheca’s EconoRoute™ prescription delivery software supports the demand with an easy-to-use, low-cost, one-stop solution for pharmacies of all sizes.

“Leva Capital is thrilled to announce the addition of iApotheca into our investment portfolio,” said Eddie Gobran, Managing Partner. “Their strategy aligns with our vision of investing in health technology that will improve the healthcare experience for Canadians. We are confident in iApotheca’s team to execute their strategy and deliver a great experience to pharmacies across Canada.”

EconoRoute™ includes features that make it an ideal delivery solution for any business. Its unique physics-based instant routing and real-time driver tracking are high-performance tools. Built-in pay-at-the-door functionality also makes it easy for businesses to track accounting.

iApotheca’s years of expertise in supporting pharmacies in doing business more efficiently make EconoRoute™ more than just another prescription delivery service.  The software has the added benefit of built-in compliance tools, cold-chain prioritization, and inherent patient privacy measures, all crucial for compliance. Taken together, these tools make EconoRoute™ a must-have for prescription delivery.

“Willowgrove Pharmacy has been using EconoRoute™ since its inception. After spending much time researching delivery platforms, EconoRoute™ came out the clear winner,” said Devon Elias, owner of Willowgrove Pharmacy in Manitoba. “The application does everything we need it to do. Optimization of routes, easy set up of regular repeat deliveries, tracking and signature requirements are all in one application, allowing for a single program to be our delivery central. Willowgrove Pharmacy employs three full-time positions for delivery of product and services and EconoRoute™ easily organizes it all.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy